Skip to main content
SpringerLink
Log in

Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The BCR-ABL1-negative myeloproliferative neoplasms (MPN) share an increased risk of thrombotic and hemorrhagic complications. Risk factors for hemorrhage are less well defined than those for thrombosis. Because patients with CALR mutations have higher platelet counts compared to JAK2 V617F-mutated patients, bleeding rates may be increased in this group. Our aim was to retrospectively evaluate whether acquired von Willebrand disease (AvWD), thrombocytosis, mutational status, or treatment history are associated with bleeding in a cohort of MPN patients. Using an electronic database, MPN patients seen between 2005 and 2013 were retrospectively identified using ICD-9 codes and billing records. A bleeding event was defined as one that was identified in the medical record and graded based on the Common Terminology Criteria for Adverse Event (CTCAE) version 4.0. Among 351 MPN patients, 15.6 % experienced 64 bleeding event types. There was no association of bleeding with mutational status, gender, MPN subtype, aspirin use, prior thrombosis, or platelet count at presentation. There was an association between bleeding and older age at diagnosis. aVWD was identified in six patients. In this single-center retrospective study, bleeding events were identified in 15 % of patients, and associated with older age at diagnosis. aVWD was rarely tested for in this cohort.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88:508–16.

    Google Scholar 

  2. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodegherio F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:2813–6.

    Article  Google Scholar 

  3. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.

    Article  CAS  PubMed  Google Scholar 

  4. Duan Y, Nie J, Zhang Z, Ji C. Acquired von Willebrand syndrome in a case of polycythemia vera resulting in recurrent and massive bleeding events in the pleural and abdominal cavity. Blood Coagul Fibrinolysis. 2015;26(1):101–3.

    Article  PubMed  Google Scholar 

  5. Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716–9.

    Article  CAS  PubMed  Google Scholar 

  6. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med. 1994;23(2):73–7.

    PubMed  Google Scholar 

  7. Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev. 2010;24(6):227–32.

    Article  PubMed  Google Scholar 

  8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and Important changes. Blood. 2009;114:937–51.

    Article  CAS  PubMed  Google Scholar 

  9. Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125(13):2029–37.

    Article  CAS  PubMed  Google Scholar 

  10. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost. 2013;39(1):101–11.

    CAS  PubMed  Google Scholar 

  11. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80.

    Article  PubMed  Google Scholar 

  12. Squizzato A, Romualdi E, Passamonti F, Middeldorp S. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. Cochrane Database Syst Rev. 2013;4:CD006503. doi:10.1002/14651858.CD006503.pub3.

  13. Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651–8.

    Article  PubMed  Google Scholar 

  14. Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

    Article  PubMed  Google Scholar 

  16. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer. 1991;67(11):2926–30.

    Article  CAS  PubMed  Google Scholar 

  17. Passamoni F, Brusamolino E, Lazzarino M, Baraté C, Klersky C, Orlandi E, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85(10):1011–8.

    Google Scholar 

  18. Borowczyk M, Wotjtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydlowska L, et al. The JAK2 eV617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thromb Res. 2015;135(2):272–80.

    Article  CAS  PubMed  Google Scholar 

  19. Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.

    Article  CAS  PubMed  Google Scholar 

  21. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–5.

    Article  CAS  PubMed  Google Scholar 

  23. Budde U, van Genderen PJ. Acquired von Willebrand Disease in Patients with High Platelet Counts. Semin Thromb Hemost. 1997;23(5):425–31.

    Article  CAS  PubMed  Google Scholar 

  24. Budde U, Scharf RE, Franke P, Hartmann-Budde K, Dent J, Ruggeri ZM. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 1993;82(6):1749–57.

    CAS  PubMed  Google Scholar 

  25. Mital A, Prejzner W, Wsiatkowska-Stodulska R, Hellmann A. Factors predisposing to acquired von Willebrand syndrome during the course of polycythemia vera—retrospective analysis of 142 consecutive cases. Thromb Res. 2015 (epub ahead of print).

Download references

Acknowledgments

The authors wish to acknowledge and thank David Dittmann, who assisted with CALR mutation analysis and Dr. David Green for his critical review of our manuscript.

Author information

Author notes

    Authors and Affiliations

    1. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 1020, Chicago, IL, 60611, USA

      Elizabeth M. Kander, Sania Raza, Anaadriana Zakarija, Brandon J. McMahon & Brady L. Stein

    2. Division of Hematology and Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA

      Zheng Zhou

    3. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA

      Juehua Gao

    Authors
    1. Elizabeth M. Kander
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Sania Raza
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Zheng Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Juehua Gao
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Anaadriana Zakarija
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Brandon J. McMahon
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Brady L. Stein
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Brady L. Stein.

    Ethics declarations

    Conflict of interest

    The authors declare that they have no conflict of interest.

    Additional information

    E. M. Kander and S. Raza contributed equally to the work.

    This research was presented, in part, at the 56th American Society of Hematology Annual Meeting and Exposition, December 6–9, 2014, San Francisco, California.

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Kander, E.M., Raza, S., Zhou, Z. et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol 102, 587–593 (2015). https://doi.org/10.1007/s12185-015-1871-4

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s12185-015-1871-4

    Keywords

    Search

    Navigation